Sanofi sig­nals a big in­ter­est in on­col­o­gy as it adds a can­cer R&D star to the board

It’s not com­mon for Big Phar­ma to put the CMO of a small biotech com­pa­ny on the board. But that’s ex­act­ly what Sanofi chair­man Serge Wein­berg is do­ing, and it says a lot about the fu­ture di­rec­tion the phar­ma gi­ant is tak­ing as Paul Hud­son con­tin­ues to build out what he hopes will be a far more ex­cit­ing pipeline.

Ear­li­er this week Wein­berg is­sued a state­ment say­ing that An­toine Yver, the CMO at Medicxi start­up Centes­sa, is be­ing put up for one of their in­de­pen­dent board posts as he beefs up the sci­en­tif­ic bench on the board. That’s pret­ty much a dead cert as these things go.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER